Tyrosine kinase inhibitors in lung adenocarcinoma with epidermal growth factor receptor mutation
Keywords:
lung neoplasms, survival, tyrosine kinase inhibitorAbstract
Introduction: Genetic alterations, including mutations in the epidermal growth factor receptor, occur in lung cancer. Gefitinib and osimertinib are approved for the treatment of non-small cell lung cancer with this mutation; they demonstrate high response and survival rates compared to chemotherapy.
Objective: To evaluate the effectiveness of tyrosine kinase inhibitors in patients with lung adenocarcinoma with mutations in the epidermal growth factor receptor.
Method: A prospective study was conducted in 29 patients with non-small cell lung cancer with adenocarcinoma histology, with mutations in the epidermal growth factor receptor, treated with tyrosine kinase inhibitors. The variables studied were: response to treatment, adverse events, progression-free survival and overall survival. Descriptive statistics summary measures and survival estimates were used by the Kaplan-Meier method and the log-rank test in the comparison of the curves.
Results: An objective response rate of 70.3% was achieved. The median overall survival and progression-free survival months were 19.9 (95% CI: 12.6-27.2) and 14.8 (95% CI: 3.6-25.9). Adverse events were classified as mild.
Conclusions: Treatment with tyrosine kinase inhibitors targeting the epidermal growth factor receptor mutation is effective and safe in patients with pulmonary adenocarcinoma with an epidermal growth factor receptor mutation.
Downloads
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [Internet]. CA Cancer J Clin. 2024; 74(3):229-63. DOI: 10.3322/caaa.21834
Niederhuber J, Armitage J, Doroshow J, Kastan M, Teper J. Oncología clínica. 6ta edición. España: Editorial Elsevier; 2020.
De Vita VT, Rosenberg SA, Lawrence TS. Cancer Principles & Practice of Oncology. Primer of the molecular biology of cancer. 3ra edición. Philadelphia: Editorial Wolters Kluwer; 2021.
Farris M, Larkin-Kaiser K, Scory T, Boyne D, Wilner K, Pastel M, et al. Network meta-analysis of first -line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival [Internet]. Future Oncol. 2020; 16(36):3107-16. DOI: 10.2217/fon-2020-0541
Flores YI, Neninger E, Páramo DL, Ortiz RA, Alfonso S, Alsina SC, et al. Diagnóstico y tratamiento del cáncer de pulmón. Programa Integral para el control del Cáncer en Cuba. La Habana: Editorial Ciencias Médicas; 2020.
Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology [Internet]. J Natl Compr Canc Netw. 2024; 22(4):249-74. DOI: 10.6004/jnccn.2204.0023
Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. ESMO Guidelines Committee. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [Internet]. Ann Oncol. 2023; 34(4):339-57. DOI: 10.1016/j.annonc.2022.12.009
Remon J, Soria JC, Peters S on behalf of the ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy [Internet]. Ann Oncol. 2021; 32(12):16371642. DOI: 10.1016/j.annonc.2021.08.1994
Abourehab M, Alqahtani A, Youssif B, Gouda A. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism [Internet]. Molecules. 2021; 26(21):6677. DOI: 10.3390/molecules26216677
Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [Internet]. Eur J Cancer. 2009; 45(2): 228-47. DOI: 10.53347/rlD-19147
Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the commonterminology criteria for adverse events (CTCAE-version5.0) to evaluate the severity of adverse events of anticancer therapies [Internet]. Actas Dermo-Sifiliograficas. 2021; 112(1):90-2. DOI: 10.1016/j.ad.2019.05.009
Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, et al. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma (IPASS) [Internet]. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699
Han J, Park K, Kim S, Lee D, Kim H, Kim H, et al. First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung [Internet]. J Clin Oncol. 2012; 30(10):1122-28. DOI: 10.1200/JCO.2011.36.8456
Takeda K, Hida T, Santo T, Ando M, Seto T, Satoushi M, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continuo platinum doublet chemotherapy in Japanese patients with advanced non -small cell lung cancer. Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203) [Internet]. J Clin Oncol. 2010;28(5):753-60. DOI: 10.1200/JCO.2009.23.3445
Nieva J, Reckamp KL, Potter D, Taylor A, Sun P. Retrospective Analysis of Real‑World Management of EGFR‑Mutated Advanced NSCLC, After First‑Line EGFR‑TKI Treatment: US Treatment Patterns, Attrition, and Survival Data [Internet]. Drugs - Real World Outcomes. 2022; 9(3):333-45. DOI: 10.1007/s40801-022-00302-w
Hung YL , Liu H, Wampfler JA, Tazelaar HD , Li Y, Peikert T, et al. Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation [Internet]. J Cancer Res Clin Oncol. 2022; 148(8):2099-2114. DOI: 10.1007/s00432-021-03766-5
Cáceres H, Varona L, Nenínger E, Basanta D, Duvergel D, Carrillo C, et al. Tratamiento con inhibidores tirosina cinasa en pacientes con cáncer de pulmón [Internet]. Rev Cub de Oncol. 2022 [acceso: 22/12/2023]; 20(1):e_173 Disponible en: https://revoncologia.sld.cu/index.php/onc/article/view/173
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFRMutated Advanced Non-SmallCell Lung Cancer [Internet]. N Eng J Med. 2018;378(2):11325. DOI: 10.1056/NEJMoa1713137
Abourehab M, Alqahtani A, Youssif B, Gouda A. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism [Internet]. Molecules. 2021; 26(21):6677. DOI: 10.3390/molecules26216677
Singh S, Sadhukhan S, Sonawane A. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight [Internet]. Biochim Biophys Acta Rev Cancer. 2023; 1878(6):188967. DOI: 10.1016/j.bbcan.2023.188967
Vaid A, Gupta A, Momi G. Overall survival in stage IV EGFR mutation-positive NSCLC: comparing first-, second- and third- generation EGFR-TKIs [Internet]. Int J Oncol. 2021;58(2):171-84. DOI: 10.3892/ijo.2021.5168
Lu HL, Jie GL, Wu YL. Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials [Internet].
Expert Opin Emerg Drugs. 2022; 27(2):111-26. DOI: 10.1080/14728214.2022.2063836
Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC [Internet]. N Engl J Med. 2020; 382(1):41-50. DOI: 10.1056/NEJMoa191366
Li X, Zhai Z, Zhu Y, Zhou H. Comparison of Gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of Osimertinib and EGFR Gene mutation [Internet]. Pak J Med Sci. 2022;38(6):1589-94. DOI: 10.12669/pjms.38.6.5456
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Yoanna Ivette Flores Vega, Diana Laura Páramo González, Alejandro Manuel Perez Fonteboa, Sofia de Alsina Sarmiento, Janet Lamadrid García, Ángel René Elejalde Larinaga, Claudia Elejalde Tamao, Danay Corrales Otero, Iniris Greca Santana Alvarez, Alexander Oretega Crballosa, Maydelin Frontela Noda, Iris Beatriz Inguanzo Valdés, Ramón Ropero Toirat
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who have publications with this Journal accept the following terms:
- The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
- The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
- Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.
